| Name | : | CNDAJI |
| Website | : | Visit Website |
| Blog | : | Visit Blog |
| Social Links | : |
Located in Guangzhou, China, Guangzhou Daji Medical Science and Technology Co., Ltd.(hereinafter referred to as “DaJiMed”) is dedicated in R&D, manufacturing, marketing and sales of blood filtration products, mainly on premium disposable leukocyte reduction filters. With over 20 years' experience on leukocyte filtration, DaJiMed has obtained more than 30 patents. With the goal of enabling a safer supply of blood transfusion products, DaJiMed membrane multi-modification technology has been developed to better remove leukocytes(WBCs) from blood. Our 4th-gen filter's leukocyte reduction rate is able to reach 99.9999%, exceeding current international standards. Its low hemolysis rate, low WBCs residual rate, fast filtration etc., also demonstrate DaJiMed as unique in China and premium in the world.
Cndaji14 Nov, 2024Entertainment
At Guangzhou Daji Medical Science and Technology Co., Ltd., we specialize in high-performance platelet leukoreduction filters designed to ensure the safety and quality of blood transfusions. Our innovative filters effectively reduce leukocyte levels, minimizing the risk of transfusion-related complications.
DaJiMed's leukoreduction filters are specifically designed to support blood bag factories in reducing leukocyte content in transfused blood. We partner with global manufacturers to offer high-quality filtration systems that ensure safe, leukocyte-free blood for patients requiring transfusions, such as those suffering from thalassemia, leukemia, or other transfusion-related conditions. Our filters also help reduce the risk of transfusion-transmitted infections and platelet refractoriness.
DaJiMed coating solution is composed of multi-modified polymers that can significantly enhance the interaction between filter membrane and WBCs by modifying the membrane fiber shape and density. By different modification methods on membrane surface, platelet can be activated or protected in different blood products to further enhance WBC capture capability or guarantee its platelet recovery.
With over 20 years' experience on leukocyte filtration, DaJiMed has obtained more than 30 patents. With the goal of enabling a safer supply of blood transfusion products, DaJiMed membrane multi-modification technology has been developed to better remove leukocytes(WBCs) from blood. Our 4th-gen filter's leukocyte reduction rate is able to reach 99.9999%, exceeding current international standards. Its low hemolysis rate, low WBCs residual rate, fast filtration etc., also demonstrate DaJiMed as unique in China and premium in the world.
Cacuocbongda01 Com
88aa
5u Bet
Wps Office
S8club
Ok365
Nn55
78win
Callie Sienna
S8club – Thế Giới Game Đỉnh Nhất